Abstract
The authors have carried out the laboratory and clinical studies of cefoperazone (CPZ). The results were as fbllows:
The sensitivity was estimated by plate dilution method on 26 strains of S.aureus, E.coli and K. pneumoniae, 25 strains of P.aeruginosa, 14 strains of Salmonella sp.and 9 strains of GM resistant P.aeruginosa is olated from patient S.The distribution of sensitivity of S.aureus was 1.56-25mcg/ml and the peak of distribution was 3.13mcg/ml.The growth of 96.2% of E.coli was inhibited at concentration of less than 12.5mcg/ml.The growth of 50.0% of K.pneumoniae was in hibited at concentration of less than 6.25mcg/ml.The peak of distribution of P.aeruginosa was 12.5-25mcg/ml (GM sensitive) and 12.5mcg/ml (GM resistant). CPZ was given by drip infusion for 30 minutes at a single dose of 25mg/kg to 2 children, and by drip infusion for 60 minutes at a single dose of 46.9mg/kg to a child.The serum mean level of CPZ was 127.5±8.5mcg/ml at 30 minutes, 30.5±7.5mcg/ml at 1 hour, 235±3.5mcg/ml at 2 hours, 10.5±1.5mcg/ml at 4 hours and 6.8±2.4mcg/ml at 6 hours after administration at a single dose of 25mg/kg, respectively.The serum level was 102.0mcg/ml at 1 hour, 32mcg/ml at 2 hours,.14.5mcg/ml at 5 hours and 12.5mcg/ml at 7 hours after administration at a single dose of 46.9mg/kg.Half-life time was 92 minutes.
The mean urinary excretion rate was 32.0±7.3%in the drip infusion for 30 minutes up to 8 hours after administration.
CPZ was effective in 6 of 8 cases with pediatric bacterial infections.
No side effects were observed except for 1 case with elevation of GOT.
